Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ. Bojang KA, et al. Among authors: kester ke. Vaccine. 2005 Jul 14;23(32):4148-57. doi: 10.1016/j.vaccine.2005.03.019. Epub 2005 Apr 15. Vaccine. 2005. PMID: 15964483 Clinical Trial.
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR. Stoute JA, et al. Among authors: kester ke. J Infect Dis. 1998 Oct;178(4):1139-44. doi: 10.1086/515657. J Infect Dis. 1998. PMID: 9806046 Clinical Trial.
Primaquine prophylaxis against malaria.
Heppner DG Jr, Gasser RA Jr, Kester KE. Heppner DG Jr, et al. Among authors: kester ke. Ann Intern Med. 1999 Mar 16;130(6):536; author reply 536-7. doi: 10.7326/0003-4819-130-6-199903160-00009. Ann Intern Med. 1999. PMID: 10075625 No abstract available.
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. Lalvani A, et al. Among authors: kester ke. J Infect Dis. 1999 Nov;180(5):1656-64. doi: 10.1086/315074. J Infect Dis. 1999. PMID: 10515829 Clinical Trial.
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.
Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D. Keitel WA, et al. Among authors: kester ke. Vaccine. 1999 Oct 14;18(5-6):531-9. doi: 10.1016/s0264-410x(99)00221-2. Vaccine. 1999. PMID: 10519944 Clinical Trial.
Malaria vaccines: triumphs or tribulations?
Ballou WR, Kester KE, Stoute JA, Heppner DG. Ballou WR, et al. Among authors: kester ke. Parassitologia. 1999 Sep;41(1-3):403-8. Parassitologia. 1999. PMID: 10697893 Review.
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group. Kester KE, et al. J Infect Dis. 2001 Feb 15;183(4):640-7. doi: 10.1086/318534. Epub 2001 Jan 24. J Infect Dis. 2001. PMID: 11170991 Clinical Trial.
77 results